Lakefront Biotherapeutics | GLPG - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
argenx SE USD 417M 62M 2026-06
AstraZeneca USD 5.8B 735M 2026-06
Biogen USD 709.7M 155.4M 2026-06
Genmab DKK 205M 39M 2026-06
Gilead Sciences USD 1.52B 70M 2026-06
GlaxoSmithKline GBP 2.19B 75M 2026-06
GRIFOLS EUR 289M 8M 2026-06
Hikma Pharmaceutical USD 288M 149M 2025-12
Incyte USD 351.73M 23.64M 2026-06
Merck EUR 1.57B 49M 2026-06
Neurocrine Biosciences USD 383.1M 64.6M 2026-06
Novartis USD 3.24B 101M 2026-06
Roche Holding CHF 6.37B 908M 2026-06
Sanofi EUR 2.63B 307M 2026-06
UCB EUR 1.47B 193M 2025-12
Vertex Pharmaceuticals USD 582.2M 88.5M 2026-06